Real world cost of human epidermal receptor 2-positive metastatic breast cancer patients: a longitudinal incidence-based observational costing study in the Netherlands and Belgium
Corresponding Author
G.W.J. Frederix PhD
Post-Doctoral Researcher in Health Technology Assessment
Science Faculty, Department of Pharmaceutical Sciences, Utrecht University, Utrecht, the Netherlands
Correspondence address: Geert W.J. Frederix, Science Faculty, Department of Pharmaceutical Sciences, Utrecht University, Universiteitsweg 99, 3584 CG Utrecht, Netherlands (e-mail: [email protected]).Search for more papers by this authorJ.L. Severens PhD
Professor of Evaluation in Health Care
Department of Health Policy and Management, Erasmus University Rotterdam, Rotterdam, the Netherlands
Search for more papers by this authorA.M. Hövels PhD
Assistant Professor in Health Technology Assessment
Science Faculty, Department of Pharmaceutical Sciences, Utrecht University, Utrecht, the Netherlands
Search for more papers by this authorJ.G.C. van Hasselt PhD
Post-Doctoral Researcher
Faculty of Science, Leiden Academic Centre for Drug Research, Leiden, the Netherlands
Search for more papers by this authorM.J.J. Hooiveld PhD
Associate Medical Director
Vertex Pharmaceuticals, Haarlem, the Netherlands
Search for more papers by this authorP. Neven MD, PhD
Gynaecological Oncologist
Multidisciplinary Breast Centre, UZ Leuven, Leuven, Belgium
Search for more papers by this authorJ.A.M. Raaijmakers PhD
Professor Pharmaceutical Technology Assessment
Science Faculty, Department of Pharmaceutical Sciences, Utrecht University, Utrecht, the Netherlands
Search for more papers by this authorJ.H.M. Schellens MD, PhD
Medical Oncologist
Science Faculty, Department of Pharmaceutical Sciences, Utrecht University, Utrecht, the Netherlands
Departments of Clinical Pharmacology and Molecular Pathology, The Netherlands Cancer Institute, Amsterdam, the Netherlands
Department of Pharmacy and Pharmacology, Slotervaart Hospital/Netherlands Cancer Institute, Amsterdam, the Netherlands
Search for more papers by this authorCorresponding Author
G.W.J. Frederix PhD
Post-Doctoral Researcher in Health Technology Assessment
Science Faculty, Department of Pharmaceutical Sciences, Utrecht University, Utrecht, the Netherlands
Correspondence address: Geert W.J. Frederix, Science Faculty, Department of Pharmaceutical Sciences, Utrecht University, Universiteitsweg 99, 3584 CG Utrecht, Netherlands (e-mail: [email protected]).Search for more papers by this authorJ.L. Severens PhD
Professor of Evaluation in Health Care
Department of Health Policy and Management, Erasmus University Rotterdam, Rotterdam, the Netherlands
Search for more papers by this authorA.M. Hövels PhD
Assistant Professor in Health Technology Assessment
Science Faculty, Department of Pharmaceutical Sciences, Utrecht University, Utrecht, the Netherlands
Search for more papers by this authorJ.G.C. van Hasselt PhD
Post-Doctoral Researcher
Faculty of Science, Leiden Academic Centre for Drug Research, Leiden, the Netherlands
Search for more papers by this authorM.J.J. Hooiveld PhD
Associate Medical Director
Vertex Pharmaceuticals, Haarlem, the Netherlands
Search for more papers by this authorP. Neven MD, PhD
Gynaecological Oncologist
Multidisciplinary Breast Centre, UZ Leuven, Leuven, Belgium
Search for more papers by this authorJ.A.M. Raaijmakers PhD
Professor Pharmaceutical Technology Assessment
Science Faculty, Department of Pharmaceutical Sciences, Utrecht University, Utrecht, the Netherlands
Search for more papers by this authorJ.H.M. Schellens MD, PhD
Medical Oncologist
Science Faculty, Department of Pharmaceutical Sciences, Utrecht University, Utrecht, the Netherlands
Departments of Clinical Pharmacology and Molecular Pathology, The Netherlands Cancer Institute, Amsterdam, the Netherlands
Department of Pharmacy and Pharmacology, Slotervaart Hospital/Netherlands Cancer Institute, Amsterdam, the Netherlands
Search for more papers by this authorFinancial disclosure
PhD student (G.W.J. Frederix) was funded by an unrestricted grant from GlaxoSmithKline, the Netherlands.
Abstract
Currently, no country-specific metastatic breast cancer (MBC) observational costing data are available for the Netherlands and Belgium. Our aim is to describe country-specific resource use and costs of human epidermal receptor 2 (HER-2)-positive MBC in the Netherlands and Belgium, making use of real-world data.
The eligibility period for patient selection was from April 2004 to April 2010. Inclusion and retrospective data collection begins at the time of first diagnosis of HER-2-positive MBC during the eligibility period and ends 24 months post-index diagnosis of MBC or at patient death.
We identified 88 eligible patients in the Netherlands and 44 patients in Belgium. The total costs of medical treatment and other resource use utilisation per patient was €48 301 in the Netherlands and €37 431 in Belgium. Majority of costs was related to the use of trastuzumab in both countries, which was 50% of the total costs in the Netherlands and 56% in Belgium respectively.
Our study provides estimates of resource use and costs for HER-2-positive MBC in the Netherlands and Belgium. We noticed various differences in resource use patterns between both countries demonstrating caution is needed when transferring cost estimates between countries.
References
- Bang H. & Tsiatis A. (2000) Estimating medical costs with censored data. Biometrika 87, 329–343.
- Beleidsregel ziekenhuiszorg (2012) Available at: http://www.nza.nl/regelgeving/beleidsregels/ziekenhuiszorg/BR-CU-2065.
- Belgisch Centrum voor Farmacotherapeutische informatie (2012) Available at: http://www.bcfi.be/.
- Bercez C., Lebrun T., Bonneterre M.E., Selke B., Lenne X. & Bonneterre J. (1999) [Advanced breast cancer: an evaluation of the cost of recurrence]. Bulletin Du Cancer 86, 585–590. available from: PM:10417432.
- Bonastre J., Jan P., Barthe Y. & Koscielny S. (2012) Metastatic breast cancer: we do need primary cost data. Breast 21, 384–388. available from: PM:22520336.
- Cameron D., Casey M., Press M., Lindquist D., Pienkowski T., Romieu C.G., Chan S., Jagiello-Gruszfeld A., Kaufman B., Crown J., Chan A., Campone M., Viens P., Davidson N., Gorbounova V., Raats J.I., Skarlos D., Newstat B., Roychowdhury D., Paoletti P., Oliva C., Rubin S., Stein S. & Geyer C.E. (2008) A phase III randomized comparison of lapatinib plus capecitabine versus capecitabine alone in women with advanced breast cancer that has progressed on trastuzumab: updated efficacy and biomarker analyses. Breast Cancer Research and Treatment 112, 533–543. available from: PM:18188694.
- CFH rapport (2012a) Available at: http://www.cvz.nl/binaries/live/cvzinternet/hst_content/nl/documenten/cfh-rapporten/2011/cfh1109-cabazitaxel-jevtana.pdf.
- CFH rapport (2012b) Available at: http://www.cvz.nl/binaries/live/cvzinternet/hst_content/nl/documenten/cfh-rapporten/2009/cfh0901+lapatinib+tyverb.pdf.
- CFH rapport (2012c) Available at: http://www.cvz.nl/binaries/content/documents/cvzinternet/nl/documenten/cfh-rapporten/2007/cfh0710+bevacizumab+avastin.pdf.
- CFH rapport (2012d) Available at: http://www.cvz.nl/binaries/live/cvzinternet/hst_content/nl/documenten/cfh-rapporten/2010/cfh1012-trastuzumab-herceptin.pdf.
- Chung C.T. & Carlson R.W. (2003) Goals and objectives in the management of metastatic breast cancer. The Oncologist 8, 514–520. available from: PM:14657529.
- Cocquyt V., Moeremans K., Annemans L., Clarys P. & Van Belle S. (2003) Long-term medical costs of postmenopausal breast cancer therapy. Ann Oncol 14 (7), 1057–1063.
- Colozza M., de Azambuja E., Personeni N., Lebrun F., Piccart M.J. & Cardoso F. (2007) Achievements in systemic therapies in the pregenomic era in metastatic breast cancer. The Oncologist 12, 253–270. available from: PM:17405890.
- Cost-effectiveness of herceptin (2012) Available at: http://www.feb.ugent.be/nl/Ondz/wp/Papers/wp_03_180.pdf.
- Dahlberg L., Lundkvist J. & Lindman H. (2009) Health care costs for treatment of disseminated breast cancer. European Journal of Cancer 45, 1987–1991. available from: PM:19398326.
- Dodwell D., Wardley A. & Johnston S. (2006) Postmenopausal advanced breast cancer: options for therapy after tamoxifen and aromatase inhibitors. Breast (Edinburgh, Scotland) 15, 584–594. available from: PM:16504510.
- Drucker A., Skedgel C., Virik K., Rayson D., Sellon M. & Younis T. (2008) The cost burden of trastuzumab and bevacizumab therapy for solid tumours in Canada. Current Oncology 15, 136–142. available from: PM:18596891.
- Drummond M., O'Brien B., Stoddart G. & Torrance G. (1997) Methods for the Economic Evaluation of Health Care Programmes, 2nd edn. Oxford University Press, New York, USA. Ref Type: Generic.
- Foster T.S., Miller J.D., Boye M.E., Blieden M.B., Gidwani R. & Russell M.W. (2011) The economic burden of metastatic breast cancer: a systematic review of literature from developed countries. Cancer Treatment Reviews 37, 405–415. available from: PM:21477928.
- Garrison L.P., Jr, Neumann P.J., Erickson P., Marshall D. & Mullins C.D. (2007) Using real-world data for coverage and payment decisions: the ISPOR Real-World Data Task Force report. Value in Health 10, 326–335. available from: PM:17888097.
- Hakkaart-van Roijen L., Tan S.S. & Bouwmans C.A.M. (2012) Manual for cost research. Methods and unit-prices for economic evaluations in health care (in Dutch). College voor zorgverzekeringen. Geactualiseerde versie 2010.
- Honoraria prijzen en vergoedingen (2012) Available at: http://www.riziv.be/insurer/nl/rate/index.htm.
- van den Hout W.B., van der Linden Y.M., Steenland E., Wiggenraad R.G., Kievit J., de Haes H., Leer J.W. & For the Dutch Bone Metastasis Study Group (2003) Single- versus multiple-fraction radiotherapy in patients with painful bone metastases: cost-utility analysis based on a randomized trial. J Natl Cancer Inst 95 (3), 222–229.
- Hurley S.F., Huggins R.M., Snyder R.D. & Bishop J.F. (1992) The cost of breast cancer recurrences. British Journal of Cancer 65, 449–455. available from: PM:1558803.
- Larg A. & Moss J.R. (2011) Cost-of-illness studies: a guide to critical evaluation. Pharmacoeconomics 29, 653–671. available from: PM:21604822.
- Matter-Walstra K.W., Dedes K.J., Schwenkglenks M., Brauchli P., Szucs T.D. & Pestalozzi B.C. (2010) Trastuzumab beyond progression: a cost-utility analysis. Annals of Oncology 21, 2161–2168. available from: PM:20444849.
- Medicijnkosten (2012) Available at: www.medicijnkosten.nl.
- Medische en niet medische kosten van kankerpatiënten (2012) Available at: https://hiva.kuleuven.be/resources/pdf/publicaties/R1407.pdf.
- Norum J., Olsen J.A., Wist E.A. & Lonning P.E. (2007) Trastuzumab in adjuvant breast cancer therapy. A model based cost-effectiveness analysis. Acta Oncologica (Stockholm, Sweden) 46, 153–164. available from: PM:17453363.
- Performance-Based Risk-Sharing Arrangements (2012) Available at: http://www.ispor.org/taskforces/documents/ISPOR-Performance-Based-Risk-Sharing-Arrangements-TF-Final-Draft-Report.pdf
- Poncet B., Colin C., Bachelot T., Jaisson-Hot I., Derain L., Magaud L., Fournel-Federico C., Mousseau M., Tigaud J.D., Jacquin J.P. & Trillet-Lenoir V. (2009) Treatment of metastatic breast cancer: a large observational study on adherence to French prescribing guidelines and financial cost of the anti-HER2 antibody trastuzumab. American Journal of Clinical Oncology 32, 369–374. available from: PM:19381078.
- Rijksinstituut voor Ziekte-en invaliditeitsverzekering (2012) Available at: http://www.riziv.fgov.be/homenl.htm.
- Slamon D.J., Leyland-Jones B., Shak S., Fuchs H., Paton V., Bajamonde A., Fleming T., Eiermann W., Wolter J., Pegram M., Baselga J. & Norton L. (2001) Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. The New England Journal of Medicine 344, 783–792. available from: PM:11248153.
- Stokes M.E., Thompson D., Montoya E.L., Weinstein M.C., Winer E.P. & Earle C.C. (2008) Ten-year survival and cost following breast cancer recurrence: estimates from SEER-medicare data. Value in Health 11, 213–220. available from: PM:18380633.
- Thomas R.J., Williams M., Marshall C., Glen J. & Callam M. (2009) The total hospital and community UK costs of managing patients with relapsed breast cancer. British Journal of Cancer 100, 598–600. available from: PM:19223909.
- Uyl-de Groot C.A., de Groot S. & Steenhoek A. (2010) The economics of improved cancer survival rates: better outcomes, higher costs. Expert Review of Pharmacoeconomics and Outcomes Research 10, 283–292. available from: PM:20545593.
